Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Iovance Biotherapeutics (IOVA) over the last 8 years, with Q3 2025 value amounting to $76.9 million.

  • Iovance Biotherapeutics' Total Non-Current Liabilities changed N/A to $76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.9 million, marking a year-over-year change of. This contributed to the annual value of $77.7 million for FY2024, which is 907.39% down from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Total Non-Current Liabilities stood at $76.9 million.
  • Iovance Biotherapeutics' 5-year Total Non-Current Liabilities high stood at $106.6 million for Q1 2024, and its period low was $70.6 million during Q1 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Total Non-Current Liabilities value was $79.8 million (recorded in 2025), while the average stood at $83.4 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Total Non-Current Liabilities soared by 5095.45% in 2024, and later tumbled by 2852.93% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Total Non-Current Liabilities stood at $85.4 million in 2023, then dropped by 9.07% to $77.7 million in 2024, then decreased by 1.04% to $76.9 million in 2025.
  • Its last three reported values are $76.9 million in Q3 2025, $79.8 million for Q2 2025, and $76.2 million during Q1 2025.